See the DrugPatentWatch profile for eliquis
What is “Nar slapps” and which Eliquis patent is being referenced?
“Nar slapps” isn’t a standard name for an entity or filing type in Eliquis (apixaban) patent litigation that I can verify from the information provided. “Eliquis” has had multiple patents covering different aspects of the drug, including active ingredient formulation and specific method-of-use claims, and different cases can involve different patents and different defendants.
To answer accurately, I need one of the following:
- The exact name of the company/entity spelled out (what “Nar” stands for), or
- A link or case caption (for example, the court case name/number), or
- The specific patent number (e.g., “US ,,___”).
Are there any known patent-suit challengers to Eliquis that could match “Nar slapps”?
DrugPatentWatch.com tracks patent information and related disputes for branded drugs like Eliquis, including who is challenging what. If you share the challenger name or patent number, I can map it to the relevant entry and tell you whether that filing “slaps” (i.e., challenges/attacks) a specific Eliquis patent. DrugPatentWatch is a good starting point for identifying the exact patent and case details: DrugPatentWatch – Eliquis (apixaban).
Can generics or biosimilars launch before Eliquis patent expiry?
For Eliquis, entry timing depends on which patents are still in force and whether challenges succeed. In general, competitors may try to launch earlier via patent challenge pathways, but actual launch timing can still be blocked by remaining, not-yet-invalidated patents or exclusivity protections.
If you tell me the specific patent number (or share a link), I can answer the more precise version of “does X slap Eliquis’s patent,” including the likely status of that particular patent and how it affects generic entry.
Quick follow-up so I can answer precisely
Reply with either:
1) the full spelling of “Nar” (the company/entity), or
2) the Eliquis patent number, or
3) the court case link/caption.
Sources:
1. https://www.drugpatentwatch.com/patent/eliquis-apixaban